Please use this identifier to cite or link to this item:
Title: Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Filiation: Servicio de Oncología. Hospital Universitario de Fuenlabrada
Issue Date: Dec-2020
Publisher: Elsevier BV
Citation: Breast.2020 Dec;(54):286-292
Abstract: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from February 2015 to November 2017.
PMID: 33242755
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Breast.pdf785.82 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons